<i>EGFR</i>Amplification in Metastatic Colorectal Cancer

Abstract

Patients with EGFR-amplified mCRC represent a biologically defined subgroup and merit dedicated clinical trials with novel and more potent EGFR-targeting strategies beyond single-agent monoclonal antibodies.